For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Scholar Rock, Inc.

USPTO Granted Patents = 30

EPO Patents = 11

Trademarks = 3

Forward Citations = 204

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Thomas Schurpf (18 out of 18 patents)

Michelle Marie Straub (18 out of 18 patents)

Nagesh K Mahanthappa (12 out of 19 patents)

4. Justin W Jackson (11 out of 11 patents)

5. Stefan Wawersik (10 out of 10 patents)

6. Abhishek Datta (9 out of 9 patents)

7. Adriana Donovan (8 out of 11 patents)

8. Gregory John Carven (8 out of 18 patents)

9. Christopher Littlefield (7 out of 7 patents)

10. Caitlin Stein (6 out of 6 patents)

11. Matthew Salotto (6 out of 6 patents)

12. Katherine Jane Turner (6 out of 14 patents)

13. Allan Capili (4 out of 4 patents)

14. Kevin B Dagbay (4 out of 4 patents)

15. Christopher Chapron (4 out of 4 patents)

30 patents: Sort by Forward Citations

1. 12454570 - Compositions and methods for growth factor modulation (2025-10-28),

2. 12358992 - LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof (2025-07-15),

3. 12338279 - Selective and potent inhibitory antibodies of myostatin activation (2025-06-24),

4. 12297262 - RGMC-selective inhibitors and use thereof (2025-05-13),

5. 12281159 - TGFβ antibodies, methods and uses (2025-04-21),

6. 12252531 - Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors (2025-03-18),

7. 12173059 - LTBP complex-specific inhibitors of TGFβ and uses thereof (2024-12-24),

8. 12122823 - Isoform-selective TGFB1 inhibitors and use thereof (2024-10-22),

9. 12006359 - Methods for altering body composition by administering anti-pro/latent myostatin antibodies (2024-06-11),

10. 11925683 - Compositions for making and using anti-Myostatin antibodies (2024-03-12),

11. 11827698 - Compositions and methods for growth factor modulation (2023-11-28),

12. 11643459 - TGFβ1-binding immunoglobulins and use thereof (2023-05-09),

13. 11439704 - Methods for using anti-myostatin antibodies (2022-09-13),

14. 11365245 - LTBP complex-specific inhibitors of TGFβ and uses thereof (2022-06-21),

15. 11214614 - LTBP complex-specific inhibitors of TGFβ and uses thereof (2022-01-04),

Scholar Rock is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines to treat serious diseases. With their proprietary platform, they target the activation of TGF-beta for therapeutic purposes. They aim to bring transformative therapies to patients with a focus on diseases driven by fibrosis, immuno-oncology, and neuromuscular disorders. Scholar Rock's commitment to scientific excellence and patient-centric approach drives their efforts to advance novel therapies and address unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

30 Patents

#74 in Cambridge, MA

#642 in Massachusetts

#10,875 in US

#21,212 in the World

Cambridge, MA, United States of America

Scholar Rock, Inc.

Forward Citations = 204

43 inventors:

Thomas Schurpf (18 out of 18 patents)

Michelle Marie Straub (18 out of 18 patents)

Nagesh K Mahanthappa (12 out of 19 patents)

4. Justin W Jackson (11 out of 11 patents)

5. Stefan Wawersik (10 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…